Top Biotech Companies in Denver & Boulder, CO (64)
Life sciences. Research. Precision manufacturing. If your life’s calling is in any of these or related fields, you need to know Beckman Coulter Life Sciences. Our mission is to empower those seeking answers to life’s important scientific and healthcare questions. Since 1935, the Beckman name has been synonymous with technologies that simplify and automate complex biomedical testing. Decades later, our...
InDevR is a global leader in progressive new analytical technologies that enable accelerated development and manufacturing of vaccines and other biotherapeutics. Key products include our VaxArray portfolio of our game-changing multiplexed potency assays for vaccines and the Cypher One system for digital imaging and automated interpretation of hemagglutination assays.
Materion (NYSE: MTRN) is one of the world’s premier advanced materials solutions providers. At Materion, we are committed to developing, manufacturing and marketing highly engineered advanced materials for global customers across a wide range of markets, including consumer electronics, defense and science, industrial and aerospace, automotive electronics, telecommunications infrastructure, appliances, medical and energy. Our products, processes and expertise help enable...
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission...
The Sequencing Center, a next generation genome sequencing company, offers affordable genome sequencing, bioinformatics, and genome data management for research, pharmaceutical, and clinical organizations. Our services are designed for organizations performing research on bacterial, viral, and human-oriented projects.
Asimov builds tools to program living cells. By integrating mammalian synthetic biology, computer-aided design, and machine learning, our multi-disciplinary team is advancing the design and manufacture of biologics and gene therapies.
Asimov's Top Stability & Growth Strengths
Strategic Partnerships: Meaningful partnerships with blue‑chip players (e.g., Cytiva, LOTTE Biologics, Novo Nordisk, AGC Biologics) signal third‑party validation and channels for broader adoption of its platform.
Product Line Growth: Product launches and updates across CHO Edge, LV Edge, and AAV Edge (including stable AAV producer cell lines and CHO Edge Rapid Pools) indicate an expanding offering aimed at biologics and gene therapy workflows.
Investor Backing & Capital Strength: Raising over $200M provides financial runway to scale R&D and commercialization and supports continued platform build‑out through 2024–2026.
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP...
KBI Biopharma's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests KBI’s integrated Selexis-enabled CLD, analytics depth, and end-to-end biologics services provide a specialist edge among mid-tier CDMOs. Successful 2024 FDA inspection and an expanded commercial contract signal credibility beyond early clinical stages.
Strategic Partnerships: Operational consolidation with Selexis and alliances such as Argonaut and Infinimmune indicate a deliberate partner strategy to broaden drug substance-to-drug product solutions. These moves position KBI to compete for larger, longer-term programs.
Customer Loyalty & Retention: The extension and expansion of a commercial manufacturing agreement with a leading pharma through 2029, with roughly $250M in additional purchases, points to durable demand from key customers. This multi-year commitment underscores continuity from early work into commercial supply.
Genapsys is a biotech company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and clinical research applications. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for a wide range of applications. Genapsys is headquartered in Redwood...
Aytu BioPharma (NASDAQ: AYTU) is a dynamic specialty pharmaceutical company with a growing commercial portfolio of prescription medicines addressing complex conditions, with a focus on ADHD and other common conditions. Our evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As we continue on this trajectory, we continue to evaluate novel therapeutics to in-license or acquire....
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Smith & Nephew's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show mid-single-digit underlying growth through 2024–2025, with management reiterating guidance for continued growth in 2026. Early 2026 updates indicate broad-based contributions across units despite some subsegment variability.
Profitability: Trading profit and margins improved, supported by execution of the 12‑Point Plan and the transition to the RISE strategy. Management is guiding to further profit growth alongside higher returns.
Healthy Cash Flow: Free cash flow strengthened in 2025 with guidance for robust generation in 2026. Share repurchases completed and newly announced buybacks signal confidence and disciplined capital allocation.
Our DATA for LIFE® mantra celebrates Pyxant Labs’ participation in an industry which saves lives. We fulfill an essential role in the drug development process. We have developed seminal capabilities directly supporting a cure for hepatitis, antiviral therapeutics for HIV, a fundamental understanding of Alzheimer’s Disease, antisense therapeutics, and now therapeutics for COVID-19. Founded in 2000, Pyxant Labs is a leading...
With 30+ years of experience, 28+ locations, and 2,000+ clinical studies conducted, Elite Clinical Network (ECN) is a trusted leader in clinical research. Our dedicated network of research sites is built on personalized service, investigator diversity, and rigorous quality processes to ensure excellence in every study. Backed by a professional corporate management team, we partner with top physicians across diverse specialties...
TriSalus Life Sciences is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.
We believe in the power of technology to improve lives, from new opportunities and mission-critical functionality to user experience. Our team is proud to partner with passionate companies focused on reducing energy consumption, curing disease, improving education, building smart cities, and more – and with leading Cloud providers, including Amazon Web Services (AWS) and Microsoft Azure.
Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development. We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to...
Forge Biologics is a gene therapy contract development and manufacturing organization (CDMO) and clinical-stage therapeutics developer. The company helps scientists, physicians, biotechnology and pharmaceutical companies, and patient groups bring life-changing gene therapies from concept to patients. Its end-to-end capabilities include plasmid and AAV manufacturing, process and analytical development, cGMP production, fill and finish, and integrated regulatory support for transformative medicines...
Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major...
At Accure, we are wholly committed to developing revolutionary solutions to provide a long- lasting, durable treatment for acne. We know that acne can have a devastating social, psychological, physical, and economic impact on patients around the world. We are pioneering transformative solutions that will answer this unmet need and have a positive and profound impact on patients and providers worldwide.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
We believe in harnessing science for human good. And so we work day and night, around the world, to deliver answers for all your health questions—whether you’re a provider, drug developer, hospital, medical researcher or patient. That means everything from advancing diagnostic testing to helping launch new drugs, to offering new perspectives through data - all drawing from a deep...













_1.0.jpg)





















